Company Snapshot
Overview
CLINUVEL (ASX: CUV; ADR Level 1: CLVLY; Börse Frankfurt: UR9) is a global specialty pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for the general population. As pioneers in photomedicine and the family of melanocortin peptides, CLINUVEL’s research and development has led to innovative treatments for patient populations with a clinical need for systemic photoprotection, DNA repair, repigmentation and acute or life-threatening conditions who lack alternatives.
CLINUVEL’s lead therapy, SCENESSE® (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel and Australia as the world’s first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Singapore and the USA.
SCENESSE®, PRÉNUMBRA®, and NEURACTHEL® are registered trademarks of CLINUVEL.
Company snapshot
| Facts | ASX Listed | 2001 |
|---|---|---|
| Shares on Issue | 50,127,270 | |
| Conditional performance rights | 285,582 | |
| Locations | Melbourne, Australia | Company headquarters |
| Zug, Switzerland | Swiss operational office | |
| Dublin, Ireland | EU operational office | |
| Monaco | Monaco operational office | |
| Egham, UK | UK operational office | |
| Singapore | VALLAURIX Research, Development & Innovation Centre | |
| Burlingame, US | US operational office | |
| Stock Listings | ASX | CUV |
| Börse Frankfurt | UR9 | |
| Level 1 ADR | CLVLY | |
| Key Financial Statistics FY June 2024 |
Total revenues | A$95.3m |
| Net profit | A$35.6m | |
| Cash reserves | A$183.9m | |
| Net increase in cash reserves | A$27.1m | |
| Total assets | A$231.1m | |
| Equity | A$203.0m | |
| Products | SCENESSE® (afamelanotide 16mg implant) | First-in-class photoprotective and repigmentation drug with EMA, US FDA and Australian TGA approvals for rare disease EPP. Phase IIb trial completed in Singapore for vitiligo. Trial programs for stroke and DNA Repair. |
| CUV9900 | An alpha-Melanocyte Stimulating Hormone (alpha-MSH) analogue in early development. | |
| Parvysmelanotide (VLRX001) | An alpha-Melanocyte Stimulating Hormone (alpha-MSH) analogue in early development. | |
| PRÉNUMBRA® | PRÉNUMBRA® is a liquid (non-solid) injectable formulation of afamelanotide designed for administration by a healthcare professional and intended to provide a flexible dose of afamelanotide, a synthetic analogue of natural α-melanocyte stimulating hormone. | |
| NEURACTHEL® (ACTH) | Translating its expertise in melanocortins and formulation development, CLINUVEL is commercialising NEURACTHEL® (adrenocorticotropic hormone; ACTH) in multiple dosage forms for patients in need of medical treatment. ACTH is a naturally occurring hormone which plays an important role in the production of cortisol, enabling the combat of stress and regulation of immune responses, maintenance of blood pressure, moderation of blood sugar, and regulation of metabolism. | |
| People | Dr Philippe Wolgen | CEO, Managing Director |
| Brenda Shanahan | Non-Executive Director | |
| Dr Karen Agersborg | Non-Executive Director | |
| Susan Smith | Non-Executive Director | |
| Professor Jeffrey V. Rosenfeld | Non-Executive Chair | |
| Mr Matthew Pringle | Non-Executive Director | |
| Mr Guy van Dievoet | Non-Executive Director | |
| Dr Pearl Grimes | Non-Executive Director | |
| Claire Newstead-Sinclair | Company Secretary | |
| Peter Vaughan | CFO | |
| Dr Dennis Wright | Chief Scientific Officer | |
| Lachlan Hay | Chief Operations Officer |